Search research articles
Contact Us
Filters
Showing results (41-50 of 76) with videos related to
Page
of 8
Sort By:
Expert Review of Gastroenterology & Hepatology
|
December 10, 2021
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study
Massimiliano Salati, Alessandro Rizzo, Valeria Merz, et al.
Medicina (Kaunas, Lithuania)
|
November 11, 2022
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, et al.
European Journal of Endocrinology
|
October 23, 2019
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients
Deborah Cosentini, Giuseppe Badalamenti, Salvatore Grisanti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
Francesca Corti, Sara Lonardi, Rossana Intini, et al.
Endocrine
|
July 7, 2021
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience
Camilla Bardasi, Andrea Spallanzani, Stefania Benatti, et al.
Future Oncology (London, England)
|
July 6, 2022
Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience
Francesco Caputo, Chiara Santini, Andrea Casadei-Gardini, et al.
Journal of Clinical Medicine
|
September 23, 2022
Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
Massimiliano Salati, Nicola De Ruvo, Mariano Cesare Giglio, et al.
The Oncologist
|
April 10, 2020
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials
Salvatore Corallo, Giovanni Fucà, Federica Morano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 25, 2025
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial
Eleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, et al.
BMC Cancer
|
April 8, 2025
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
Vincenzo Nasca, Francesca Bergamo, Luisa Foltran, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 76) with videos related to
Sort By:
Page
of 8
Expert Review of Gastroenterology & Hepatology
|
December 10, 2021
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study
Massimiliano Salati, Alessandro Rizzo, Valeria Merz, et al.
Medicina (Kaunas, Lithuania)
|
November 11, 2022
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, et al.
European Journal of Endocrinology
|
October 23, 2019
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients
Deborah Cosentini, Giuseppe Badalamenti, Salvatore Grisanti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors
Francesca Corti, Sara Lonardi, Rossana Intini, et al.
Endocrine
|
July 7, 2021
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience
Camilla Bardasi, Andrea Spallanzani, Stefania Benatti, et al.
Future Oncology (London, England)
|
July 6, 2022
Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience
Francesco Caputo, Chiara Santini, Andrea Casadei-Gardini, et al.
Journal of Clinical Medicine
|
September 23, 2022
Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST
Massimiliano Salati, Nicola De Ruvo, Mariano Cesare Giglio, et al.
The Oncologist
|
April 10, 2020
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials
Salvatore Corallo, Giovanni Fucà, Federica Morano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 25, 2025
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial
Eleonora Cristarella, Margherita Ambrosini, Massimo Di Maio, et al.
BMC Cancer
|
April 8, 2025
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
Vincenzo Nasca, Francesca Bergamo, Luisa Foltran, et al.
Page
of 8